alnylam pharmaceuticals inc
(ALNY:NASDAQ GS)
Executive Profile*
Judy Lieberman M.D., Ph.D.Member of Scientific Advisory Board, Alnylam Pharmaceuticals, Inc. |
| Age | Total Calculated Compensation | This person is connected to 29 board members in 2 different organizations across 2 different industries. See Board Relationships |
| -- | -- |
Background*
Dr. Judy Lieberman, M.D., Ph.D. is Professor of pediatrics at the Harvard Medical School, Director of the Division of AIDS at Harvard Medical School, and a senior investigator in the Immune Disease Institute. Dr. Lieberman is board certified in internal medicine and hematology, a widely known expert in translational medicine, and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. Dr. Lieberman and her colleagues ...
Corporate Headquarters*300 Third StreetCambridge, Massachusetts 02142 United States Phone: 617-551-8200 Fax: 617-551-8101 Board Members Memberships*There is no Board Members Memberships data available.Education*MD Harvard University MD Massachusetts Institute of Technology PhD Rockefeller University
Other Affiliations* |
Annual Compensation*There is no Annual Compensation data available.Stock Options*There is no Stock Options data available.Total Compensation*There is no Total Compensation data available. |
| Recently Viewed | |||
| ALNY:US | $28.98 USD | +0.92 |  |
COMPETITOR COMPENSATION
| Name | Position/ Company | Compensation |
| Stanley T. Crooke M.D., Ph.D. | Founder, Executive Chairman, Chief Executive Officer, President and Member of Non-Management Stock Option Committee Isis Pharmaceuticals, Inc. | $1.1M |
| George W. Hebard III, M.B.A | Interim Principal Executive Officer, Interim Chief Operating Officer and Director Enzon Pharmaceuticals Inc. | $226.4K |
| Christopher Nishan Garabedian | Chief Executive Officer, President and Director Sarepta Therapeutics, Inc. | $490.0K |
| Kleanthis G. Xanthopoulos Ph.D. | Chief Executive Officer, President and Director Regulus Therapeutics Inc. | $515.5K | Compensation as of Fiscal Year 2012. |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
